Asia
In November, Chinese researcher He Jiankui of the Southern University of Science and Technology of China announced he had used CRISPR to alter the embryos of seven couples to make them resistant to HIV. To date, a set of twins were born and there is another pregnancy. This was met by near-universal condemnation in the global scientific community.
It’s no secret that the global biopharma and life sciences industry is large. Sometimes the immense size of the industry can lead fascinating news tidbits to fall through the cracks, particularly those from smaller companies scattered across the globe. This week BioSpace will launch a new roundup of news from companies across the globe.
Accelerated Evolution Biotechnologies(AEBi)’s claims to have found a cure for cancer are, appropriately, being met with global skepticism. Learn more about it here.
Singapore-based ASLAN slashed 30 percent of its staff following a recent mid-stage failure, and California-based Aduro has cut 37 percent of employees.
In a recent study published in Scientific Reports, researchers at Kanazawa University show that an artificially synthesized molecule can exhibit compatible activities to natural molecules in its biological effectiveness.
Dengue fever affects as many as 400 million people annually and is caused by one of four related viruses transmitted by mosquitoes. The trial showed the vaccine was efficacious in preventing dengue fever by any of the four serotypes.
Singapore Exchange-listed Singapore eDevelopment Limited wishes to announce that its U.S. biomedical subsidiary, Global BioLife Inc. has a product known as 3F Antimicrobial Fragrance which shows efficacy against tuberculosis.
Taiwan Liposome Company, Ltd. announced the appointment of George Spencer-Green, MD, MS, as TLC’s new Chief Medical Officer.
This week, the U.S. Supreme Court rejected Swiss pharmaceutical company Helsinn Healthcare S.A.’s claim that Teva Pharmaceutical violated patent rights when the Israel-based company released a generic version of its anti-nausea medicine, Aloxi.
Taiwan Liposome Company, Ltd. today announced that the European Medicines Agency (EMA) has granted orphan drug designation for TLC178 for the treatment of soft tissue sarcoma.
PRESS RELEASES